

**Kevin M. Sowinski, Pharm.D.**  
**Publications**

**Refereed Articles**

1. Sowinski KM, Burlew BS, Johnson JA. Racial differences in sensitivity to oral propranolol in healthy black and white males. *Clin Pharmacol Ther* 1995;57:678-83.
2. Sowinski KM, Forrest A, Wilton JH, Taylor AM, Wilson MF, Kazierad DJ. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. *J Clin Pharmacol* 1995;35:807-14.
3. Sowinski KM, Lima JJ, Burlew BS, Massie JD, Johnson JA. Racial differences in propranolol enantiomer kinetics following simultaneous IV and oral administration. *Br J Clin Pharmacol* 1996;42:339-46.
4. Hobson AG, Sowinski KM. The use of aspirin in combination with ticlopidine following implantation of coronary artery stents. *Ann Pharmacother* 1997;31:770-2.
5. Sowinski KM, Burlew BS. Impact of CYP2D6 metabolic phenotype on propranolol pharmacokinetics and response. *Pharmacotherapy* 1997;17:1305-10.
6. Scott MK, Mueller BA, Sowinski KM, Clark WR. Dialyzer dependent changes in solute and water permeability with bleach reprocessing. *Am J Kidney Dis* 1999;33:86-97.
7. Sowinski KM, Abel SR, Clark WR, Mueller BA. Effect of gender on the pharmacokinetics of ofloxacin. *Pharmacotherapy* 1999;19:442-6.
8. Wilensky RL, Mehdi K, Sowinski KM, Baek SH, March KL. Increased intramural retention after local delivery of molecules with increased binding properties: Implications for regional delivery of pharmacologic agents or genes. *J Cardiovasc Pharmacol Ther* 1999;4:103-12.
9. Scott MK, Mueller BA, Sowinski KM. Peracetic acid-hydrogen peroxide reprocessing: the effects on dialyzer solute and water permeability. *Pharmacotherapy* 1999;19:1042-9.
10. Brophy DF, Sowinski KM, Kraus MA, Moe S, Klaunig JE, Mueller BA. Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis. *Per Dial Int* 1999;19:534-539.
11. Trujillo TN, Sowinski KM, Venezia RA, Scott MK, Mueller BA. Vancomycin assay performance in patients with acute renal failure. *Intensive Care Med* 1999;11:1291-6.
12. Mueller BA, Scott MK, Sowinski KM, Pragg KA. Noni juice (*Morinda citrifolia*): hidden potential for hyperkalemia ? *Am J Kidney Dis* 2000;35:310-2.
13. Sowinski KM, Scott SA, Carlstedt BC. An internet training module for traditional and nontraditional doctor of pharmacy students: content and evaluation. *Am J Pharm Educ* 2000;64:15-9.
14. Kingery JR, Sowinski KM, Kraus MA, Klaunig JE, Mueller BA. Vancomycin assay performance in patients receiving high permeability hemodialysis. *Pharmacotherapy* 2000;20:653-6.
15. Scott MK, Kim MA, Kraus MA, Mueller BA, Sehra RA, Altemose GT, Sowinski KM. Effect of cisapride on QT interval in patients with end stage renal disease. *Am J Cardiol* 2000;86:8: 873-875.
16. Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, Marx MA. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. *Am J Kidney Dis* 2001;37:766-776
17. Liang HL, Scott MK, Murry DJ, Sowinski KM. Determination of albumin and myoglobin in dialysate and ultrafiltrate samples by high-performance size exclusion liquid chromatography. *J Chromatogr B* 2001;754:141-51.

18. Bahouth SW, Sowinski KM, Lima JJ. Regulation of human  $\beta_1$ -adrenergic receptors and their mRNA in neuroepithelioma SK-N-MC cells: effects of agonist, forskolin and protein kinase A. *Biochem Pharmacol* 2001;62:1211-20.
19. Goldstein SL, Murry DJ, May S, Aleksic A, Sowinski KM, Blaney S. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. *Ped Neph* 2001;16:1015-8.
20. Liang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. *J Chromatogr B* 2002;772:53-63.
21. Lucksiri A, Scott MK, Mueller BA, Hamburger RA, Sowinski KM. CAHP-210 dialyzer influence on intradialytic vancomycin bioavailability. *Nephrol Dial Trans* 2002;17:1649-54.
22. Sowinski KM, Lucksiri A, Kays MB, Scott MK, Mueller BA, Hamburger RA, Levofloxacin pharmacokinetics in end-stage renal disease and removal by the CAHP-210 hemodialyzer. *Am J Kidney Dis* 2003;42:342-349
23. Overholser BR, Kays MB, Sowinski KM. Determination of gatifloxacin in human serum and urine by high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B* 2003;798:167-173
24. Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. *Artif Organs* 2003;27:808-14.
25. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effect of sevelamer and calcium acetate on the relative oral bioavailability of ciprofloxacin. *Am J Kidney Dis* 2003;42:1253-9.
26. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, Clark DO, Stroupe KT, Wu J, Deer MM, Bruner-England TE, Sowinski KM, Smith FE, Oldridge NB, Gradus-Pizlo I, Murray LL, Brater DC, Weinberger M. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. *Am J Geriatr Pharmacother* 2004;2:44-52
27. Overholser BR, Kays MB, Forrest A, Sowinski KM. Effect of sex on ciprofloxacin pharmacokinetics. *J Clin Pharmacol* 2004;44:1012-22.
28. Sowinski KM, Kays MB. Determination of ciprofloxacin concentrations in human serum and urine by HPLC with ultraviolet and fluorescence detection.. *J Clin Pharm Ther* 2004;29:381-7.
29. Sowinski KM, Kronin DA, Mueller BA, Kraus MA. Subcutaneous terbutaline use in chronic kidney disease to reduce potassium concentrations. *Am J Kidney Dis* 2005;45:1040-5.
30. Overholser BR, Kays MB, Lagvankar S, Mueller BA, Goldman M, Sowinski KM. Pharmacokinetics of intravenously administered levofloxacin in men and women. *Pharmacotherapy* 2005;25:1310-8.
31. Kays MB, Overholser BR, Lagvankar S, Goldman M, Sowinski KM. Effect of Ensure on the oral bioavailability of gatifloxacin. *Pharmacotherapy* 2005, 25:1530-5.
32. Overholser BR, Brophy DF, Sowinski KM. Anti-factor Xa activity sampling to optimally predict enoxaparin exposure post-hemodialysis, *Ther Drug Monit* 2006;28:807-12.
33. Zhang X, Overholser BR, Kays MB, Sowinski KM. Gatifloxacin pharmacokinetics in healthy men and women. *J Clin Pharmacol* 2006;46:1154-62.
34. Fagan SC, Touchette D, Smith JA, Sowinski KM, Dolovich L, Olsen KL, Cheang KI, Kolesar JM, Crismon ML, for the ACCP Research Affairs Committee. State of Science and Research in Clinical Pharmacy: A White Paper from the Research Affairs Committee of the American College of Clinical Pharmacy, *Pharmacotherapy* 2006,26:1027-40.

35. Cochran B, Sowinski KM, Fausel C, Overholser BR. Compatibility of mycophenylate mofetil with several intravenously administered drugs. *Am J Health-Sys Pharm* 2007;64:1410-4.
36. Decker BS, Mueller BA, Sowinski KM. Drug dosing in alternative hemodialysis. *Adv Chron Kid Dis* 2007, 14:e17-26.
37. Foster DR, Sowinski KM, Chow HHS, Overholser BR. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallocatechin gallate, in fasting and fed conditions. *Ther Drug Monit* 2007; 29:835-842.
38. Overholser BR, Sowinski KM. Biostatistics Primer: Part 1 (Invited Review). *Nutr Clin Pract* 2007; 22: 629 - 635.
39. Overholser BR, Sowinski KM. Biostatistics Primer: Part 2 (Invited Review). *Nutr Clin Pract* 2008, 23:76-84.
40. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA. Effect of CAHP-210 hemodialyzer on gentamicin pharmacokinetics, removal during hemodialysis and dosing. *Clin J Am Soc Neph*, 2008;3:355-61.
41. Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM. Steady-state pharmacodynamics and pharmacodynamics of meropenem in hospitalized patients. *Pharmacotherapy* 2008;28:691-8.
42. Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Coram R, Kingery J, Zipes DP, Flockhart DA, Kovacs R. Pharmacokinetics of Ibutilide in patients with heart failure. *Pharmacotherapy* 2008; 28:1461-70.
43. Smith JA, Olson KL, Sowinski KM. ACCP Student Primer: Pharmacy practice research careers. *Pharmacotherapy*, 2009; 29:1007-11.
44. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using steady-state pharmacokinetic data from hospitalized patients. *Ann Pharmacother* 2009 (epub Oct 6).
45. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalized patients. *Int J Antimicrob Ag* 2009;34:429-33.
46. Overholser BR, Sowinski KM. Development and evaluation of a biostatistics course as a required course in the Doctor of Pharmacy curriculum, *Submitted*.

### Book Chapters/Videotapes

1. Sowinski KM, Johnson JA. Angina Pectoris. In: Herfindal ET, Gourley DR (eds.) *The Textbook of Therapeutics: Disease and Drug Management*, 6th ed. Williams and Wilkins: Baltimore, MD, 1996.
2. Sowinski KM, Blank JW. *Heart Failure*. Two hour videotape for the Consultant Pharmacist Certificate Program, Purdue University, West Lafayette, IN, 1996.
4. Sowinski KM. *Pathophysiology and treatment of ischemic heart disease*. Two hour videotape for the Consultant Pharmacist Certificate Program, Purdue University, West Lafayette, IN, 1998.
5. Sowinski KM. *Pathophysiology and treatment of dyslipidemias*. Two hour videotape for the Consultant Pharmacist Certificate Program, Purdue University, West Lafayette, IN, 1998.
6. Sowinski KM. *Heart Failure*. Internet based presentation and case studies for the University of Kentucky, Continuing Education Programs ([www.rxce.org](http://www.rxce.org)), Lexington, KY, 1998-99.

7. Sowinski KM. Endothelial function and dysfunction. *Medscape Pharmacists* URL: <http://www.medscape.com/viewarticle/408573> [Accessed February, 2007].
8. Sowinski KM. Ischemic Heart Disease. In: Herfindal ET, Gourley DR (eds.) *The Textbook of Therapeutics: Disease and Drug Management*, 7th ed. Williams and Wilkins: Baltimore, MD, 2000.
9. Sowinski KM. Cardiovascular Disorders. In: Gourley DR, Gourley G (eds.) *Casebook for The Textbook of Therapeutics: Disease and Drug Management*, 7th ed. Williams and Wilkins: Baltimore, MD, 2000.
10. Sowinski KM. Angina and Myocardial Infarction. In: Tisdale JE, Miller WE (eds.) *Drug-induced diseases*, 1<sup>st</sup> edition. American Society of Health-System Pharmacy, Bethesda, MD. 2005, pp. 261-280.
11. Overholser BR, Sowinski KM. Ischemic Heart Disease. In: Helms RA, Quann DJ, Herfindal ET, Gourley DR (eds.) *The Textbook of Therapeutics: Disease and Drug Management*, 8th ed. Lippincott Williams and Wilkins: Philadelphia, PA, 2006, pp. 576-96.
12. Sowinski KM, Overholser BR. Ischemic Heart Disease, case study and answers. In: Helms RA, Quann DJ, Herfindal ET, Gourley DR (eds.) *The Textbook of Therapeutics: Disease and Drug Management*, 8th ed. Lippincott Williams and Wilkins: Philadelphia, PA, 2006, pp. 651-3, 2609-15
13. Schellhase EM, Chen JT, Jordan J, Kania DS, Overholser BR, Shepler BM, Sowinski KM, Williams CD. Pharmacology and its impact on the rehabilitation process. In: *Scientific foundations and principles of practice in musculoskeletal rehabilitation*. Magee DJ, Zachazewski JE, Quillen WS eds. St. Louis, MO: Saunders Elsevier; 2007.
14. Sowinski KM, Mueller BA. Drug Dosing in Patients with Acute Kidney Injury or Receiving Renal Replacement Therapy. In: Ronco C, Bellomo R, Kellum J (Eds.) *Critical Care Nephrology*, 2nd edition. Saunders: Philadelphia, PA, 2008.
15. Sowinski KM. Myocardial Ischemia and Myocardial Infarction. In: Tisdale JE, Miller WE (eds.) *Drug-induced diseases*, 2<sup>nd</sup> edition. American Society of Health-System Pharmacy, Bethesda, MD., 2009, (*in press*).
16. Sowinski KM, Churchill MA. Hemodialysis and Peritoneal Dialysis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds.) *Pharmacotherapy A pathophysiologic approach*, 8<sup>th</sup> edition. McGraw Hill, New York, NY., 2010, (*submitted*).

### Letters/Book Reviews/Editorials

1. Sowinski KM. *Book Review: Pharmaceutical Statistics - Practical and Clinical Applications*, Third Edition, Sanford Bolton. *Am J Pharm Ed* 1997;61:462.
2. Sowinski KM, Mueller BA. Apple juice and hyperkalaemia. *Lancet* 2001;358:841-2.
3. Sowinski KM. *Book Review: Arrhythmia Treatment and Therapy, Evaluation of Clinical Trial Evidence*, First Edition, R.L. Woosley, S.N. Singh. *Am J Pharm Ed* 2001;65:103.
4. Mueller BA, Pasko DA, Sowinski KM. Ofloxacin clearance during continuous hemofiltration. *Am J Kidney Dis* 2003;42:1326-7.
5. Sowinski KM, Clinical Twisters: Resolving Heart Failure Revolving Door. *Drug Topics Health-Sys Ed.*, 2006;7.
6. Sowinski KM, Wright JM, Greene W, et al., Preparation for the Pharmacotherapy Specialty Certification Examination, are question cues enough? *Pharmacotherapy* 2006;26;11:1675-7.
7. Sowinski KM, Overholser BO. *Book Review: Essential Statistics for the Pharmaceutical Sciences*, First Edition, Philip Rowe. *Ann Pharmacother* 2007; 41: 1747